Oxford BioDynamics PLC has successfully raised £9.9 million through a placing, direct subscriptions, and a retail offer. This involved issuing 89,228,889 new ordinary shares at an issue price of 9 pence per share. The fundraising represents approximately 35.1% of the company's issued ordinary share capital. The joint brokers and bookrunners for the placing were Shore Capital, Baden Hill, and WG Partners.

The new ordinary shares are expected to be admitted to trading on AIM, with VCT/EIS Admission effective on April 5, 2024, and General Admission effective on April 8, 2024. The shares will rank in full for all dividends and other distributions and will otherwise rank pari passu with the existing ordinary shares.

Vulpes Investment Management, controlled by Non-Executive Director Stephen Diggle, has agreed to subscribe for 2,222,222 new ordinary shares in the placing, bringing their aggregate holding to 29,653,978 ordinary shares, representing 9.5% of the Enlarged Share Capital. The transaction between the company and Vulpes Investment Management is a related party transaction.

Certain Directors and PDMRs, including persons closely associated, have participated in the fundraising by subscribing for a total of 647,776 Subscription Shares, 361,110 Placing Shares, and 472,221 PrimaryBid Shares. The beneficial holdings of these individuals before and after the fundraising have been disclosed.

The directors independent of the Vulpes Transaction have considered the terms of the Vulpes Transaction to be fair and reasonable. This fundraising will enable Oxford BioDynamics PLC to further its biotechnology endeavors in developing precision medicine tests based on the EpiSwitch® 3D genomics platform.